Sandbox: ATL: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
high serum level of CD25 | high serum level of CD25 | ||
high serum neuron‐specific enolase | high serum neuron‐specific enolase | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" | |||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 250px; color: #FFFFFF;"|'''Prognostic Factor''' | |||
! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Description''' | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Age'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |||
:* Older age at the time of diagnosis is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:* Males are associated with a worse prognosis when compared to females. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:* Patient's poor [[performance status]] is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |||
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |||
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*Deletion of [[chromosome 17]] short arm and [[chromosome 11]] long arm are associated with a worse prognosis. | |||
|- | |||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |||
:*An increased percentage of [[prolymphocyte]]s is associated with a worse prongnosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*Diffuse [[histology]] on [[bone marrow aspiration]] is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*Elevated level of [[LDH]] is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''β2-microglobulin level '''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*Elevated level of β2-microglobulin level is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface markers'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*Over expression of [[CD38]] is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*The absence of IgVH [[gene]] mutation is associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Membrane-bound proteins'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*The expression of zeta-chain-associated protein kinase 70 (ZAP) is associated with a worse prognosis. | |||
|} |
Revision as of 19:51, 24 January 2016
prognosis
Clinical form age poor clinical performance status high lactate dehydrogenase (LDH) high β2‐microglobulin high leukemic counts hypercalcemia high serum level of CD25 high serum neuron‐specific enolase
Prognostic Factor | Description |
---|---|
Age |
|
Gender |
|
Performance status |
|
Stage |
|
Lymphocyte doubling time |
|
Genetic mutations |
|
Prolymphocytes percent |
|
Histological analysis |
|
Lactate dehydrogenase (LDH) level |
|
β2-microglobulin level |
|
Lymphocyte surface markers |
|
Immunoglobulin (Ig)VH gene |
|
Membrane-bound proteins |
|
- ↑ Mahieux R, Gessain A (2007). "Adult T-cell leukemia/lymphoma and HTLV-1". Curr Hematol Malig Rep. 2 (4): 257–64. doi:10.1007/s11899-007-0035-x. PMID 20425378.
- ↑ Matutes E (2007). "Adult T-cell leukaemia/lymphoma". J Clin Pathol. 60 (12): 1373–7. doi:10.1136/jcp.2007.052456. PMC 2095573. PMID 18042693.
- ↑ Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y; et al. (2015). "Treatment and survival among 1594 patients with ATL". Blood. 126 (24): 2570–7. doi:10.1182/blood-2015-03-632489. PMID 26361794.